FR22C1021I2 - Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif - Google Patents

Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif

Info

Publication number: FR22C1021I2
Authority: FR; France
Prior art keywords: ponesimod; selective; receptor agonist; dosage regimen; regimen
Prior art date: 2014-12-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR22C1021C

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-11

Filing date

2022-06-01

Publication date

2023-04-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54843844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1021(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2022-06-01 Application filed filed Critical

2022-07-15 Publication of FR22C1021I1 publication Critical patent/FR22C1021I1/fr

2023-04-14 Application granted granted Critical

2023-04-14 Publication of FR22C1021I2 publication Critical patent/FR22C1021I2/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Obesity (AREA)
Hematology (AREA)
Otolaryngology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)

FR22C1021C 2014-12-11 2022-06-01 Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif Active FR22C1021I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP2014077469		2014-12-11
EP2015058202		2015-04-15
PCT/EP2015/079208 WO2016091996A1 (fr)	2014-12-11	2015-12-10	Régime posologique pour un agoniste de récepteur s1p1 sélectif

Publications (2)

Publication Number	Publication Date
FR22C1021I1 FR22C1021I1 (fr)	2022-07-15
FR22C1021I2 true FR22C1021I2 (fr)	2023-04-14

Family

ID=54843844

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR22C1021C Active FR22C1021I2 (fr)	2014-12-11	2022-06-01	Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif

Country Status (31)

Country	Link
US (4)	US10220023B2 (fr)
EP (2)	EP4056179A1 (fr)
JP (1)	JP6244497B1 (fr)
KR (4)	KR102427123B1 (fr)
CN (2)	CN106999461A (fr)
AU (2)	AU2015359346B2 (fr)
CA (1)	CA2968180C (fr)
CL (1)	CL2017001457A1 (fr)
CY (1)	CY1125170T1 (fr)
DK (1)	DK3256125T3 (fr)
EA (1)	EA036075B1 (fr)
ES (1)	ES2909071T3 (fr)
FR (1)	FR22C1021I2 (fr)
HR (1)	HRP20220359T8 (fr)
HU (2)	HUE057865T2 (fr)
IL (1)	IL252727B (fr)
LT (2)	LT3256125T (fr)
MX (2)	MX2020011182A (fr)
MY (1)	MY188764A (fr)
NL (1)	NL301174I2 (fr)
NO (1)	NO2022023I1 (fr)
PH (1)	PH12017501059A1 (fr)
PL (1)	PL3256125T3 (fr)
PT (1)	PT3256125T (fr)
RS (1)	RS63048B1 (fr)
SG (1)	SG11201704563RA (fr)
SI (1)	SI3256125T1 (fr)
TW (1)	TW201625242A (fr)
UA (1)	UA122064C2 (fr)
WO (1)	WO2016091996A1 (fr)
ZA (1)	ZA201704624B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT2278960T (lt)	2008-03-17	2017-02-10	Actelion Pharmaceuticals Ltd.	S1p1 receptoriaus selektyvaus agonisto dozavimo režimas
MA41139A (fr)	2014-12-11	2017-10-17	Actelion Pharmaceuticals Ltd	Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
CA2968180C (fr)	2014-12-11	2020-01-28	Actelion Pharmaceuticals Ltd	Regime posologique pour un agoniste de recepteur s1p1 selectif
JOP20190207A1 (ar)	2017-03-14	2019-09-10	Actelion Pharmaceuticals Ltd	تركيبة صيدلانية تشتمل على بونيسيمود
US11186556B1 (en)	2018-10-16	2021-11-30	Celgene Corporation	Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014897B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11013723B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014940B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Thiazolidinone and oxazolidinone compounds and formulations
CA3145269A1 (fr)	2019-07-22	2021-01-28	Michel BURCKLEN	Utilisation du ponesimod dans le traitement de la sclerose en plaques
MX2022005014A (es)	2019-10-31	2022-05-16	Idorsia Pharmaceuticals Ltd	Combinacion de un antagonista de cxcr7 con un modulador del receptor s1p1.
KR20220151625A (ko)	2020-03-06	2022-11-15	액테리온 파마슈티칼 리미티드	뇌 부피 손실을 둔화시키는 방법
MX2023010906A (es)	2021-03-17	2023-12-07	Actelion Pharmaceuticals Ltd	Sistema de dosificacion farmaceutica.
WO2023062511A1 (fr)	2021-10-11	2023-04-20	Actelion Pharmaceuticals Ltd	Méthodes de traitement de la sclérose en plaques
CA3220684A1 (fr)	2021-10-11	2023-04-20	Actelion Pharmaceuticals Ltd	Methodes de traitement de la sclerose en plaques
EP4415712A1 (fr)	2021-10-11	2024-08-21	Laboratoires Juvise Pharmaceuticals	Méthodes de traitement de la sclérose en plaques
WO2023061918A1 (fr)	2021-10-11	2023-04-20	Actelion Pharmaceuticals Ltd	Méthodes de traitement de la sclérose en plaques
US20240261267A1 (en)	2021-11-05	2024-08-08	Vanda Pharmaceuticals Inc.	Methods for treating multiple sclerosis
US20240261268A1 (en)	2022-02-11	2024-08-08	Vanda Pharmaceuticals Inc.	Methods of slowing an increase in brain ventricular volume

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0217152D0 (en)	2002-07-24	2002-09-04	Novartis Ag	Organic compounds
PL1689726T3 (pl)	2003-11-21	2011-05-31	Actelion Pharmaceuticals Ltd	Pochodne 5-(benz-(z)-ylideno)tiazolidyn-4-onu jako środki immunosupresyjne
USRE43833E1 (en)	2003-11-21	2012-11-27	Actelion Pharmaceuticals Ltd.	Thiazolidin-4-one derivatives
EP1819326B1 (fr)	2004-11-29	2014-07-02	Novartis AG	Posologie d'un agoniste du recepteur s1p
US7879821B2 (en)	2006-01-26	2011-02-01	University Of Medicine And Dentistry Of New Jersey	Method for modulating inflammatory responses by altering plasma lipid levels
US8912340B2 (en)	2006-11-23	2014-12-16	Actelion Pharmaceuticals Ltd.	Process for the preparation of 2-imino-thiazolidin-4-one derivatives
AU2007323042B2 (en)	2006-11-23	2012-12-20	Actelion Pharmaceuticals Ltd	New process for the preparation of 2-imino-thiazolidin-4-one derivatives
LT2278960T (lt)	2008-03-17	2017-02-10	Actelion Pharmaceuticals Ltd.	S1p1 receptoriaus selektyvaus agonisto dozavimo režimas
GB0819182D0 (en)	2008-10-20	2008-11-26	Actelion Pharmaceuticals Ltd	Crystalline forms
ES2760607T3 (es)	2008-12-22	2020-05-14	Novartis Ag	Régimen de dosificación para un agonista del receptor s1p
AU2009331582B2 (en)	2008-12-22	2014-03-13	Novartis Ag	Dosage regimen of an S1P receptor agonist
CN104540800B (zh)	2012-08-17	2017-05-10	埃科特莱茵药品有限公司	制备(2z,5z)‑5‑(3‑氯‑4‑((r)‑2,3‑二羟基丙氧基)苯亚甲基)‑2‑(丙亚氨基)‑3‑(邻甲苯基)噻唑烷‑4‑酮的方法及在该方法中所用的中间产物
CA2968180C (fr) *	2014-12-11	2020-01-28	Actelion Pharmaceuticals Ltd	Regime posologique pour un agoniste de recepteur s1p1 selectif
MA41139A (fr)	2014-12-11	2017-10-17	Actelion Pharmaceuticals Ltd	Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1

2015
- 2015-12-10 CA CA2968180A patent/CA2968180C/fr active Active
- 2015-12-10 WO PCT/EP2015/079208 patent/WO2016091996A1/fr active Application Filing
- 2015-12-10 PL PL15807916T patent/PL3256125T3/pl unknown
- 2015-12-10 UA UAA201707086A patent/UA122064C2/uk unknown
- 2015-12-10 DK DK15807916.0T patent/DK3256125T3/da active
- 2015-12-10 US US15/534,929 patent/US10220023B2/en active Active
- 2015-12-10 MY MYPI2017702097A patent/MY188764A/en unknown
- 2015-12-10 CN CN201580067209.2A patent/CN106999461A/zh active Pending
- 2015-12-10 SI SI201531811T patent/SI3256125T1/sl unknown
- 2015-12-10 EP EP22152212.1A patent/EP4056179A1/fr active Pending
- 2015-12-10 KR KR1020177018950A patent/KR102427123B1/ko active IP Right Grant
- 2015-12-10 RS RS20220283A patent/RS63048B1/sr unknown
- 2015-12-10 ES ES15807916T patent/ES2909071T3/es active Active
- 2015-12-10 LT LTEPPCT/EP2015/079208T patent/LT3256125T/lt unknown
- 2015-12-10 EA EA201791286A patent/EA036075B1/ru unknown
- 2015-12-10 PT PT158079160T patent/PT3256125T/pt unknown
- 2015-12-10 EP EP15807916.0A patent/EP3256125B1/fr active Active
- 2015-12-10 AU AU2015359346A patent/AU2015359346B2/en active Active
- 2015-12-10 HU HUE15807916A patent/HUE057865T2/hu unknown
- 2015-12-10 KR KR1020217032617A patent/KR102590068B1/ko active IP Right Grant
- 2015-12-10 SG SG11201704563RA patent/SG11201704563RA/en unknown
- 2015-12-10 JP JP2017531167A patent/JP6244497B1/ja active Active
- 2015-12-10 KR KR1020237034975A patent/KR20230147768A/ko not_active Application Discontinuation
- 2015-12-10 MX MX2020011182A patent/MX2020011182A/es unknown
- 2015-12-10 HR HRP20220359TT patent/HRP20220359T8/hr unknown
- 2015-12-10 CN CN202310732054.6A patent/CN117137912A/zh active Pending
- 2015-12-10 MX MX2017007638A patent/MX2017007638A/es unknown
- 2015-12-10 KR KR1020207002611A patent/KR20200013086A/ko not_active Application Discontinuation
- 2015-12-10 TW TW104141578A patent/TW201625242A/zh unknown
2017
- 2017-06-06 IL IL252727A patent/IL252727B/en active IP Right Grant
- 2017-06-07 PH PH12017501059A patent/PH12017501059A1/en unknown
- 2017-06-08 CL CL2017001457A patent/CL2017001457A1/es unknown
- 2017-07-10 ZA ZA2017/04624A patent/ZA201704624B/en unknown
2019
- 2019-01-29 US US16/261,327 patent/US10857134B2/en active Active
2020
- 2020-04-22 AU AU2020202684A patent/AU2020202684A1/en not_active Abandoned
- 2020-11-05 US US17/090,756 patent/US11771683B2/en active Active
2022
- 2022-04-07 CY CY20221100260T patent/CY1125170T1/el unknown
- 2022-05-09 NL NL301174C patent/NL301174I2/nl unknown
- 2022-05-12 HU HUS2200021C patent/HUS2200021I1/hu unknown
- 2022-05-20 LT LTPA2022505C patent/LTPA2022505I1/lt unknown
- 2022-06-01 FR FR22C1021C patent/FR22C1021I2/fr active Active
- 2022-06-10 NO NO2022023C patent/NO2022023I1/no unknown
- 2022-10-13 US US18/046,492 patent/US20230131600A1/en active Pending

Also Published As

Publication number	Publication date
PH12017501059A1 (en)	2017-11-27
ZA201704624B (en)	2022-03-30
US10857134B2 (en)	2020-12-08
JP6244497B1 (ja)	2017-12-06
HRP20220359T1 (hr)	2022-05-13
HRP20220359T8 (hr)	2022-05-27
PL3256125T3 (pl)	2022-05-09
KR20210126792A (ko)	2021-10-20
FR22C1021I1 (fr)	2022-07-15
NZ733463A (en)	2023-10-27
MX2017007638A (es)	2017-09-11
KR20170094335A (ko)	2017-08-17
EP3256125B1 (fr)	2022-01-26
EP4056179A1 (fr)	2022-09-14
LT3256125T (lt)	2022-04-11
IL252727B (en)	2021-02-28
WO2016091996A1 (fr)	2016-06-16
EA201791286A1 (ru)	2017-12-29
US20180147188A9 (en)	2018-05-31
ES2909071T3 (es)	2022-05-05
US20170319555A1 (en)	2017-11-09
EA036075B1 (ru)	2020-09-23
KR20230147768A (ko)	2023-10-23
HUE057865T2 (hu)	2022-06-28
TW201625242A (zh)	2016-07-16
IL252727A0 (en)	2017-08-31
SG11201704563RA (en)	2017-07-28
SI3256125T1 (sl)	2022-04-29
MY188764A (en)	2021-12-30
LTPA2022505I1 (fr)	2022-06-10
US10220023B2 (en)	2019-03-05
CL2017001457A1 (es)	2018-02-09
CN106999461A (zh)	2017-08-01
US20210052555A1 (en)	2021-02-25
CN117137912A (zh)	2023-12-01
AU2015359346A8 (en)	2017-08-03
KR102427123B1 (ko)	2022-07-28
DK3256125T3 (da)	2022-03-21
AU2015359346B2 (en)	2020-05-07
KR20200013086A (ko)	2020-02-05
CA2968180C (fr)	2020-01-28
AU2020202684A1 (en)	2020-05-14
NO2022023I1 (no)	2022-06-10
CA2968180A1 (fr)	2016-06-16
JP2017538706A (ja)	2017-12-28
RS63048B1 (sr)	2022-04-29
MX2020011182A (es)	2022-10-03
US11771683B2 (en)	2023-10-03
CY1125170T1 (el)	2022-07-22
US20190151292A1 (en)	2019-05-23
NL301174I1 (fr)	2022-05-09
HUS2200021I1 (hu)	2022-05-28
NL301174I2 (nl)	2022-06-09
NZ768672A (en)	2023-10-27
AU2015359346A1 (en)	2017-07-27
US20230131600A1 (en)	2023-04-27
UA122064C2 (uk)	2020-09-10
PT3256125T (pt)	2022-05-06
EP3256125A1 (fr)	2017-12-20
KR102590068B1 (ko)	2023-10-16

Publication	Publication Date	Title
FR22C1021I2 (fr)	2023-04-14	Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif
CY2022011I1 (el)	2022-07-22	Δοσολογικο σχημα για την πονεσιμοδη, εναν επιλεκτικο αγωνιστη του υποδοχεα s1p1
PL3067774T3 (pl)	2018-07-31	Urządzenie operacyjne do maszyny budowlanej
DK3212637T3 (da)	2021-07-12	Dopamin-d3-receptorantagonistforbindelser
IL247084B (en)	2019-09-26	dose fgh–18
GB201418710D0 (en)	2014-12-03	Dosage regimen
HUE053054T2 (hu)	2021-06-28	Adagolópumpa adagolókészülékhez, valamint adagolókészülék
FR3046350B1 (fr)	2018-02-16	Chariot- portoir pour un brancard.
HUP1500110A2 (hu)	2016-09-28	Vízerõgép áramló közeghez
TH1601000316A (th)	2018-02-01	อะโกนิสต์ของตัวรับวาโซเพรสซิน-2
GB201501974D0 (en)	2015-03-25	Network subscription for a new device
GB201419433D0 (en)	2014-12-17	Dopamine D3 receptor antagonist compounds
GB201419430D0 (en)	2014-12-17	Dopamine D3 receptor antagonist compounds
TH1601002277A (th)	2017-08-24	เครื่องจักรสำหรับจ่ายภาชนะ
GB201418708D0 (en)	2014-12-03	Dosage regimen
ES1134965Y (es)	2015-03-20	Máquina dispensadora de bebidas mediante dosificación
GB201400171D0 (en)	2014-02-19	Dosage regimen